Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $52.75 USD
Change Today -0.21 / -0.40%
Volume 521.7K
ALR On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Key Developments

Alere Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reports Impairments for the Quarter Ended June 30, 2015; Provides Earnings Guidance for the Year Ending December 31, 2015

Alere Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenue of $629,156,000 against $647,398,000 a year ago. Operating income was $91,837,000 against operating loss of $5,749,000 a year ago. Income from continuing operations before provision (benefit) for income taxes was $36,603,000 against loss from continuing operations before provision (benefit) for income taxes of $54,564,000 a year ago. Income from continuing operations was $20,263,000 against loss from continuing operations of $57,941,000 a year ago. Net income attributable to the company and subsidiaries was $19,904,000 against net loss attributable to the company and subsidiaries of $45,088,000 a year ago. Income from continuing operations was $0.17 against loss from continuing operations of $0.77 a year ago. Basic and diluted net income per common share was $0.17 against basic and diluted loss per share of $0.61 a year ago. Non-GAAP adjusted operating income was $115,225,000 against $97,264,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $48,250,000 against $36,184,000 a year ago. Non-GAAP adjusted income per diluted common share from continuing operations was $0.54 against $0.39 a year ago. Non-GAAP adjusted net income per diluted common share was $0.54 against $0.42 a year ago. Non-GAAP adjusted net Revenues were $629,356,000 against $647,771,000 a year ago. Non-GAAP EBITDA was $141,260,000. Cash flow from operating activities was $4,148,000. Capital expenditures were $21,637,000. For the six months, the company reported net revenue of $1,237,309,000 against $1,272,637,000 a year ago. Operating income was $119,244,000 against $29,247,000 a year ago. Income from continuing operations before provision (benefit) for income taxes was $16,309,000 against loss from continuing operations before provision (benefit) for income taxes of $64,446,000 a year ago. Income from continuing operations was $12,714,000 against loss from continuing operations of $60,791,000 a year ago. Net income attributable to the company and subsidiaries was $229,044,000 against net loss attributable to the company and subsidiaries of $50,642,000 a year ago. Basic and diluted net income from continuing operations was $0.02 per share against basic and diluted net loss from continuing operations of $0.87 per share a year ago. Basic and diluted net income per common share was $2.54 against basic and diluted loss per share of $0.74 a year ago. Non-GAAP adjusted operating income was $230,003,000 against $206,744,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $94,171,000 against $82,068,000 a year ago. Non-GAAP adjusted income per diluted common share from continuing operations was $1.07 against $0.90 a year ago. Non-GAAP adjusted net income per diluted common share was $1.06 against $0.96 a year ago. Non-GAAP adjusted net revenue was $1,237,756,000 against $1,273,429,000 a year ago. Non-GAAP EBITDA was $273,641,000. Cash flow from operating activities was $32,526,000. Capital expenditures were $47,284,000. For the quarter, the company reported impairment and loss on disposition, net of $5,542,000 against $638,000 a year ago. For the year ending December 31, 2015, the company expects net revenue to be in the range of $2.5 billion to $2.6 billion. Non-GAAP adjusted net income from continuing operations available to common stockholders in the range of $2.40 to $2.50 per diluted share.

Alere Inc. to Report Q2, 2015 Results on Aug 04, 2015

Alere Inc. announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Aug 04, 2015

Alere Inc., Q2 2015 Earnings Call, Aug 04, 2015

Alere Inc., Q2 2015 Earnings Call, Aug 04, 2015

Alere Inc. Appoints Geoffrey S. Ginsburg to the Company's Board of Directors

Alere Inc. announced the election of Geoffrey S. Ginsburg, M.D., Ph.D. to the Company's Board of Directors, effective immediately. Dr. Ginsburg is a founding director of the Center for Applied Genomics & Precision Medicine and also a professor of Medicine, Pathology and Biomedical Engineering, both at Duke University. In addition to his current positions at Duke University, Dr. Ginsburg also serves as an expert panel member for Genome Canada, as a member of the Board of External Experts for the National Heart, Lung and Blood Institute, as Co-Chair of the Institute of Medicine's Roundtable on Genome-Based Research to Human Health, as a member of the advisory council for the National Center for Accelerating Translational Science, as co-Chair of the Cures Acceleration Network, co-chair of the Global Genomic Medicine Collaborative, and as a member of the World Economics Forum'sGlobal Agenda Council on the Future of the Health Sector.

Alere Inc. Receives U.S. Food and Drug Administration CLIA Waiver for Alere i Strep A Rapid Molecular Test

Alere Inc. announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere™ i Strep A test. The test, which was cleared for marketing by the FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less. With CLIA waiver, the Alere i Strep A test will be available in a broad range of healthcare settings, including physician offices, hospital emergency rooms, and retail and walk-in clinics in the United States. The Strep A test is the second assay on the Alere i molecular platform, which initially received 510(k) clearance for the detection and differentiation of influenza A and B virus in 2014. In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $52.75 USD -0.21

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $139.52 USD -1.74
BioMerieux €102.05 EUR +1.30
Getinge AB kr192.40 SEK -0.20
PerkinElmer Inc $49.48 USD +0.04
STERIS Corp $64.69 USD -0.36
View Industry Companies
 

Industry Analysis

ALR

Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 2.9x
Price/Cash Flow 18.7x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.